These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20811368)

  • 21. The use of hepatotoxic signals to predict the safety of peroxisome proliferator-activated receptor agonists.
    Hastings KL
    Expert Opin Drug Metab Toxicol; 2006 Aug; 2(4):489-92. PubMed ID: 16859399
    [No Abstract]   [Full Text] [Related]  

  • 22. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
    Arulmozhi DK; Kurian R; Bodhankar SL; Veeranjaneyulu A
    J Pharm Pharmacol; 2008 Sep; 60(9):1167-73. PubMed ID: 18718120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trial watch: SGLT2 inhibitor shows promise in type 2 diabetes.
    Nat Rev Drug Discov; 2010 Mar; 9(3):182. PubMed ID: 20190779
    [No Abstract]   [Full Text] [Related]  

  • 24. Homocysteine competes for the peroxisome proliferator-activated receptor nuclear receptors.
    Hayden MR
    J Cardiometab Syndr; 2008; 3(1):70-1. PubMed ID: 18326982
    [No Abstract]   [Full Text] [Related]  

  • 25. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative structure-activity relationship analysis of thiazolidineones: potent antidiabetic compounds.
    Vishvakarma VK; Singh P; Dubey M; Kumari K; Chandra R; Pandey ND
    Drug Metabol Drug Interact; 2013; 28(1):31-47. PubMed ID: 23417104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PPAR agonists, - Could tissue targeting pave the way?
    Bugge A; Holst D
    Biochimie; 2017 May; 136():100-104. PubMed ID: 27916640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.
    Pourcet B; Fruchart JC; Staels B; Glineur C
    Expert Opin Emerg Drugs; 2006 Sep; 11(3):379-401. PubMed ID: 16939380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes.
    Moller DE; Greene DA
    Adv Protein Chem; 2001; 56():181-212. PubMed ID: 11329854
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus.
    Rosenson RS
    Am J Cardiol; 2007 Feb; 99(4A):96B-104B. PubMed ID: 17307062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PPAR-gamma agonists and their role in type 2 diabetes mellitus management.
    Bermúdez V; Finol F; Parra N; Parra M; Pérez A; Peñaranda L; Vílchez D; Rojas J; Arráiz N; Velasco M
    Am J Ther; 2010; 17(3):274-83. PubMed ID: 20216208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of a thiazolidinedione compound as a new antidiabetic drug].
    Toyota T
    Nihon Rinsho; 2001 Nov; 59(11):2211-8. PubMed ID: 11712410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
    Derosa G; Sahebkar A; Maffioli P
    J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear peroxisome proliferator-activated receptors and thiazolidinediones.
    Grinberg A; Park KW
    Int Anesthesiol Clin; 2005; 43(2):1-21. PubMed ID: 15795559
    [No Abstract]   [Full Text] [Related]  

  • 36. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?
    Feldman PL; Lambert MH; Henke BR
    Curr Top Med Chem; 2008; 8(9):728-49. PubMed ID: 18537685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
    Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
    Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Acupuncture Intervention Reduced Weight Gain Induced by Hypoglycemic Agents through Food Intake-related Targets in Central Nervous System].
    Jing XY; Ou C; Lu SF; Zhu BM
    Zhen Ci Yan Jiu; 2015 Dec; 40(6):510-3. PubMed ID: 26887217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pioglitazone: beyond glucose control.
    de Pablos-Velasco P
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1057-67. PubMed ID: 20670183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.